Performance of Various Pharmacokinetic Parameters in Predicting Vancomycin Serum Concentrations

Sano, Kuniaki; Suzuki, Norihiro; Saitoh, Mitsuhiro

doi:10.5649/jjphcs.34.1

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…found that ME was −4·10 for uncorrected SCR and 0·33 for corrected SCR (21), and Sano et al. reported MEs of −3·34 and 0·43, respectively (22). In our data, the ME for pmClcr enzyme was −6·29 and that for pmClcr Jaffe was −2·12 with SCR enzyme < 0·6 mg/dL (Table 4).…”

Section: Discussionmentioning

confidence: 99%

Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods

Tsuji

Hiraki

Mizoguchi

et al. 2009

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods

Tsuji

Hiraki

Mizoguchi

et al. 2009

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application

et al. 2021

View full text Add to dashboard Cite

Validating the Effectiveness of Switching the Vancomycin TDM Analysis Software Based on the Predictive Accuracy

et al. 2017

View full text Add to dashboard Cite

Based on the predictive performance in our previous study, we switched the therapeutic drug monitoring (TDM) analysis software for dose setting of vancomycin (VCM) from``Vancomycin MEEK TDM analysis software Ver2.0'' (MEEK) to``SHIONOGI-VCM-TDM ver.2009'' (VCM-TDM) in January 2015. In the present study, our aim was to validate the eŠectiveness of the changing VCM TDM analysis software in initial dose setting of VCM. The enrolled patients were divided into two groups, each having 162 patients in total, who received VCM with the initial dose set using MEEK (MEEK group) or VCM-TDM (VCM-TDM group). We compared the rates of attaining the therapeutic range (trough value; 10 20 mg/mL) of serum VCM concentration between the groups. Multivariate logistic regression analysis was performed to conˆrm that changing the VCM TDM analysis software was an independent factor related to attaining the therapeutic range. Switching the VCM TDM analysis software from MEEK to VCM-TDM improved the rate of attaining the therapeutic range by 21.6％ (MEEK group: 42.6％ vs. VCM-TDM group: 64.2％, p＜0.01). Patient age  65 years, concomitant medication (furosemide) and the TDM analysis software used VCM-TDM were considered to be independent factors for attaining the therapeutic range. These results demonstrated the eŠectiveness of switching the VCM TDM analysis software from MEEK to VCM-TDM for initial dose setting of VCM.

show abstract

Performance of Various Pharmacokinetic Parameters in Predicting Vancomycin Serum Concentrations

Cited by 5 publications

References 13 publications

Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods

Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods

Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application

Validating the Effectiveness of Switching the Vancomycin TDM Analysis Software Based on the Predictive Accuracy

Contact Info

Product

Resources

About